p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). - Wikidata - wikimedia - TriplyDB

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

http://www.wikidata.org/entity/Q33695954

about

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy PP2A: The Achilles Heal in MDS with 5q Deletion Role of ribosomal protein mutations in tumor development (Review)Established and emerging targeted therapies in the myelodysplastic syndromes.Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).Clonal evolution in myelodysplastic syndromes Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome.TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes.Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment.Recent Advances in the 5q- Syndrome.Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help?p53 protein expression in patients with myelodysplasia treated with allogeneic bone marrow transplantation.A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis.Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.Bridge-Induced Translocation between NUP145 and TOP2 Yeast Genes Models the Genetic Fusion between the Human Orthologs Associated With Acute Myeloid Leukemia.Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.Bone marrow fibrosis at diagnosis is associated with TP53 overexpression and adverse prognosis in low-risk myelodysplastic syndrome.Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.Increased p53 protein expression as a potential predictor of early relapse after hematopoietic stem cell transplantation in children with acute myelogenous leukemia.Relevance of prognostic factors in the decision-making of stem cell transplantation in Myelodysplastic Syndromes.Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.Myelodysplastic syndrome with del (5q) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with complex karyotype.

P2860

Q26778754-D49CDA6C-1D99-4A56-A457-DACEA9E08B46 Q27010653-0C05398C-2EB3-46CD-8CCA-86A41D8111EC Q27690852-AFE8A468-DF9E-4D97-850B-EC4A751A8102 Q28068265-E03239E6-7B36-41A5-8312-AFB04698F583 Q30245476-34B660A9-C594-4157-AF7D-1E103ACE8F29 Q33836662-CA4B3756-80B9-4F09-8532-1E12459452F8 Q34555597-4EF820A7-FF70-4974-A07B-EBD2C85B23BF Q35016534-53608625-D288-4ADE-9264-DA7AA2AD7E54 Q36544120-0751FFD4-50FB-4FCD-86F9-C6B56568A900 Q36609771-6231DEEB-0121-43AF-8D21-7634D72F28B3 Q37074311-FDC63565-0CBF-41DD-97B2-4DB4CE6E2629 Q37665288-70975E92-2CB7-4AAE-BF64-3AD6C0AD6C7B Q38451022-6DBFCC04-B523-4CF0-81F1-8EFF74F9A81D Q38527837-1DFDD4A1-5FB4-4769-9AF3-27C8C0355A4A Q38716306-C15DF22A-7142-41B9-A944-08EF9D3B6B77 Q38739506-DD3015E6-39E9-49A8-BABE-740639C73FE8 Q38764824-2F5B7344-9AAB-4BEF-BB6F-5CABA3E2DE35 Q39116272-23332432-9994-4FC3-A3FC-00A011A4EA08 Q39155501-D14C643E-65F6-4E60-8BB0-9B2E28441CDE Q39811365-37356E6C-D163-4588-833E-8B4FEF62DDDD Q41039704-15930C6F-10BD-4C4C-A859-9752C739C201 Q41156034-623694E4-B367-4131-9E7E-86E7BD674BD6 Q41572334-4CFA8ACD-8ECA-49AE-AC25-8D52D80F8BA6 Q42334124-7312D533-EDA2-46E1-9533-5E10FEDCF2AE Q42369829-6C09778C-D0AA-406F-A5EB-08434A2EC22B Q42376082-B617378C-F00E-4544-85CA-1BC4C138BD81 Q42391595-900D24B0-1157-4FFD-BB71-584042516CCF Q42923384-51E96875-9155-4D98-B570-7E365E813EFC Q45923418-EC0C52AE-256A-41C0-98A2-8AA7922465A0 Q48104500-7F3A1277-FA4F-4949-AC26-DC42BDEF0BBE Q50213851-6768EB36-7EBE-431F-95A8-18D35984115A Q52777531-BABAE3CE-26CB-406D-A17F-FA2A9FDE99DA Q52912438-17F90ED4-EFC8-4DCC-968D-D0F6B644F278 Q52941727-5DD3F82F-BA28-4A5D-86A9-DF2F46C0DD22 Q53064376-B3E1335B-73DC-4286-B9E5-10E48A8356A9 Q54223187-BC171334-970F-47A4-ACA8-01E007D47EF3

P2860

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

http://www.wikidata.org/entity/Q33695954

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

p53 protein expression indepen ...... lastic syndromes with del(5q).

@ast

p53 protein expression indepen ...... lastic syndromes with del(5q).

@en

type

label

p53 protein expression indepen ...... lastic syndromes with del(5q).

@ast

p53 protein expression indepen ...... lastic syndromes with del(5q).

@en

prefLabel

p53 protein expression indepen ...... lastic syndromes with del(5q).

@ast

p53 protein expression indepen ...... lastic syndromes with del(5q).

@en

P1433

Q33695954-6BFFDDCB-34CE-47A9-B0D3-9502E6CB9FA7

P1476

Q33695954-1F6E1A3E-2626-44C3-9EB4-797DDD889635

P2093

Q33695954-12A9326A-13C7-4AA3-9D85-0BCEB0C58E99

Q33695954-3D7FADAD-52AF-4202-89EF-E160581390AA

Q33695954-3E887AAC-3F75-433D-A80B-C86E02994A72

Q33695954-41C76582-73FC-41C9-8607-4E4B5F9518F7

Q33695954-489631FC-7E0B-4EA6-A699-40501A6A6ADE

Q33695954-48D76893-D1C8-4D11-87F1-D1670E26DDBB

Q33695954-4FA87F11-4980-4F8A-B271-89BC600D6173

Q33695954-8236E250-77DA-4040-A94A-AC661648B2E4

Q33695954-9E3A64B3-C4AA-44B6-B524-A9F9E82144AF

Q33695954-A5673FBD-B964-428A-903F-CB3FF57B25A0

P2860

Q33695954-0E58BF5B-A44C-4E6F-8E84-4EFE07258A41

Q33695954-14798DD7-6E8B-499A-AB63-A55FE1010B13

Q33695954-17D69B10-115F-417B-8AA7-F26B7ED1053F

Q33695954-1EBCA33C-8202-4313-B0F1-118ADF27555D

Q33695954-276224BF-CC39-4FF0-900D-FCA49D5043F7

Q33695954-297634F8-4F62-4364-836B-87EB7F050809

Q33695954-3018E675-D622-4846-A93C-721CEEDF7428

Q33695954-32FB9994-37E1-4F56-90A7-323BD4154EDA

Q33695954-34E4B69B-D10D-46AB-95CD-D4572B9DF0CA

Q33695954-3AAA8E4E-BD70-4C21-88F7-EEA3A1599918

P304

Q33695954-0701E6E9-F7F9-4482-9FE4-F91794B72B45

P31

Q33695954-DF504D28-FA49-4B03-8AB2-7CF86ABEE277

P356

Q33695954-4BE33EB1-218A-4E0B-9D47-C902A693627F

P433

Q33695954-7EFF6BD6-7835-4F6C-B3D7-A3BEBECC6167

P478

Q33695954-4F71847D-CEB9-4B4F-B9EE-2D2E14F4E9EB

P50

Q33695954-30B795F9-384E-44DE-8CE6-25339F33C819

Q33695954-610167B6-62DD-426D-9A06-B39DB4FFA2F8

Q33695954-E8BF2020-FF0A-4790-83EA-2D16DCC0AA62

Q33695954-F21950A6-6C0B-43D3-B951-C94919E309E0

P577

Q33695954-FBD151FB-0076-408E-9791-A8ACC88875D9

P5875

Q33695954-C0CEC07D-518A-4127-A333-E05271DC0252

P698

Q33695954-7B4A9613-B1AB-4140-AA59-D1EF412350E0

P932

Q33695954-0F09846B-CEF7-485E-8E4F-B75ACA358581

P356

HAEMATOL.2013.098103

P1433

P1476

p53 protein expression indepen ...... lastic syndromes with del(5q).

@en

P2093

András Matolcsy

http://www.w3.org/2001/XMLSchema#string

Anna Porwit

http://www.w3.org/2001/XMLSchema#string

Austin Kulasekararaj

http://www.w3.org/2001/XMLSchema#string

David Bowen

http://www.w3.org/2001/XMLSchema#string

Dominik Selleslag

http://www.w3.org/2001/XMLSchema#string

Eva Hellström-Lindberg

http://www.w3.org/2001/XMLSchema#string

Ghulam J Mufti

http://www.w3.org/2001/XMLSchema#string

Gudrun Göhring

http://www.w3.org/2001/XMLSchema#string

Guillermo Sanz

http://www.w3.org/2001/XMLSchema#string

Jay Backstrom

http://www.w3.org/2001/XMLSchema#string

P2860

Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes

International scoring system for evaluating prognosis in myelodysplastic syndromes

European consensus on grading bone marrow fibrosis and assessment of cellularity.

Clinical effect of point mutations in myelodysplastic syndromes

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.

The MDM2-p53 interaction.

NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes.

Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome.

p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.

Study of p53 in elderly patients with myelodysplastic syndromes by immunohistochemistry and DNA analysis

P304

1041-1049

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2013.098103

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

Eva Hellström-Lindberg

Aristoteles A N Giagounidis

P577

2014-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261221459

http://www.w3.org/2001/XMLSchema#string

P698

24682512

http://www.w3.org/2001/XMLSchema#string

P932

4040908

http://www.w3.org/2001/XMLSchema#string